Gene Editing & Longevity Biotech
30-Second Executive Brief
Executive Assessment
Gene Editing & Longevity Biotech functions as a core technology within Healthcare & Life Sciences, backed by 43% sourcing coverage, though its relative influence is cooling.
- Maintains 4 mapped relationships across the graph
- 43% sourcing coverage across sourced relationships
- Tracked as core technology within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Core Technology
- Sourcing Coverage
- 43%
- Ecosystem Influence
- High
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 4
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Gene editing and longevity biotech reached a landmark inflection point in 2026: Intellia Therapeutics' in vivo CRISPR therapy lonvo-z succeeded in a Phase 3 trial for hereditary angioedema (an 87% reduction in attack rate) and began a rolling FDA submission that could make it the first approved in vivo gene-editing therapy for any disease, validating over a decade of CRISPR therapeutic development. In parallel, longevity biotech attracted massive capital inflows led by Altos Labs (more than $3 billion raised, backed by Jeff Bezos and Yuri Milner, now approaching clinical trials on cellular reprogramming) and Retro Biosciences (backed by OpenAI's Sam Altman, reaching a $1.8 billion valuation while running its first clinical trial for an Alzheimer's protein-clearance therapy), reflecting a broader shift of both venture capital and tech-industry wealth into genetic medicine and aging research as distinct, non-AI-native biotechnology categories.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Nature Biotechnology / CNBC — Intellia's CRISPR therapy achieves landmark Phase 3 successresearch
Relationship Map
The relationships surrounding Gene Editing & Longevity Biotech — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Gene editing and longevity biotech are on two very different validation timelines despite sharing the same 'genetic medicine' label
32% confidenceIntellia's lonvo-z has cleared Phase 3 with statistically robust results and is in rolling FDA submission, while Altos Labs and Retro Biosciences are still pre-trial or early-trial despite having raised far more capital combined than Intellia's clinical program.
This is InsightNodes' own interpretive read: the category is often discussed as a single 'genetic medicine' wave, but CRISPR-based gene editing for well-defined monogenic diseases (Intellia's approach) has a much clearer regulatory and clinical pathway than cellular reprogramming or protein-aggregate clearance for aging-related conditions (Altos Labs, Retro Biosciences), where the underlying biology and endpoints are far less established -- capital allocators should weight these two tracks very differently, since lonvo-z's success or failure says little about whether cellular reprogramming will similarly translate to the clinic.
InsightNodes analysis of gene-editing and longevity biotech landscape · Aug 14, 2026
Gene Editing & Longevity Biotech's Timeline
A sourced, dated history of Gene Editing & Longevity Biotech's key moments — founding to present.
Apr 2026 · Intellia's lonvo-z becomes first in vivo CRISPR therapy to succeed in Phase 3
Intellia Therapeutics' lonvo-z became the first in vivo CRISPR gene-editing therapy to succeed in a Phase 3 trial, reducing hereditary angioedema attack rates by 87% versus placebo and beginning a rolling FDA submission that could make it the first approved in vivo gene-editing therapy for any disease.